References of "Rentier, Bernard"
     in
Bookmark and Share    
Full Text
See detailWhat should be done on policy level to give Open Access in Belgium a boost? The CRef answer
Conti, Calogero; Delvaux, Bruno; Lambert, Jean-Paul et al

Diverse speeche and writing (2012)

Detailed reference viewed: 289 (20 ULg)
Full Text
See detailQu’est-ce qu’une université ?
Rentier, Bernard ULg

Speech/Talk (2012)

Detailed reference viewed: 45 (9 ULg)
Full Text
See detailThe Liège ORBi model: Mandatory policy without rights retention but linked to assessment processes
Rentier, Bernard ULg; Thirion, Paul ULg

Conference given outside the academic context (2011)

The decision to build an institutional repository at the University of Liège was taken in 2005. It took 3 years to prepare for a faultless start in November 2008. A strong communication campaign conveyed ... [more ▼]

The decision to build an institutional repository at the University of Liège was taken in 2005. It took 3 years to prepare for a faultless start in November 2008. A strong communication campaign conveyed the Open Access concept to the ULg research community. A name was coined to personalise the concept : ORBi (Open Repository and Bibliography, http://orbi.ulg.ac.be/), suggesting an improved worldwide audience. A special effort in internal communication was devoted to acceptance of the mandate. It appeared essential to make it plain that ORBi would offer an unprecedented increase in readership, but that it would only be valuable if all ULg members would abide by the new rules. Any mandate needs some coercitive persuasion. Rather than resting on advocacy, we linked internal assessment to the scientific production stored in ORBi. Those applying for promotion have no choice but to file all their production in full text. This created waves of progression. Since then, evidence for a much increased readership (about twice, http://opcit.eprints.org/) has transformed the early participants in strong advocates of the repository. 68,000 items have been filed, 41,000 (60,2%) with full text (only mandatory for documents published later that 2002). According to ROAR (http://roar.eprints.org ), out of 1,568 IRs, ORBi comes 27th for the number of references, 15th for « high activity level » and 1st for « medium activity level » (number of days with 10-99 deposits/day). ORBi is now considered a success by almost all ULg members. Its advantages to individual authors have become a better incentive than the mandate itself. [less ▲]

Detailed reference viewed: 1558 (54 ULg)
Full Text
See detailMieux vaut prévenir que guérir
Rentier, Bernard ULg

Speech/Talk (2011)

Detailed reference viewed: 40 (3 ULg)
Full Text
See detailIs Open Access just for articles in STM? Can OA books help Humanities? The Liège Experience
Rentier, Bernard ULg; Thirion, Paul ULg

Scientific conference (2011, February 25)

Detailed reference viewed: 108 (14 ULg)
Full Text
Peer Reviewed
See detailHepatitis C of genotype 2: the role of medical invasive exams.
Putzeys, V.; GERARD, Christiane ULg; Bastens, B. et al

in Acta gastro-enterologica Belgica (2011), 74(2), 277-80

BACKGROUND AND AIM: Hepatitis C virus genotype 2 is the third in order of frequency in Belgium. The aim of this study was to better define the genotype 2 carriers' epidemiology characteristics. METHODS ... [more ▼]

BACKGROUND AND AIM: Hepatitis C virus genotype 2 is the third in order of frequency in Belgium. The aim of this study was to better define the genotype 2 carriers' epidemiology characteristics. METHODS: In a database comprising 1726 viremic hepatitis C virus patient from the south part of Belgium, the files of 98 genotype 2 carriers were reviewed. RESULTS: There was a strong association between genotype 2 and the mode of transmission. The rate of contamination by invasive medical exams was very high (23%), and statistically different from the one of the others genotypes. Eligibility for antiviral therapies and the rate of sustained viral response were high. CONCLUSION: HCV genotype 2 was highly associated with transmission by invasive medical exams. [less ▲]

Detailed reference viewed: 117 (14 ULg)
Full Text
See detailSavoir rebondir
Rentier, Bernard ULg

Speech/Talk (2010)

Detailed reference viewed: 28 (2 ULg)
Full Text
See detailChercheurs, vos papiers! Les dépôts institutionnels obligatoires
Rentier, Bernard ULg

in Hermès (2010), (57), 107-108

Detailed reference viewed: 70 (19 ULg)
Full Text
See detailPrimary versus secondary failure following varicella vaccination: implications for interval between two doses-Literature review
Bonanni, Paolo; Gershon, Anne; Gershon, Michael et al

Poster (2010)

Detailed reference viewed: 62 (12 ULg)
Full Text
Peer Reviewed
See detailVaricella vaccination in Europe – taking the practical approach
Bonanni, Paolo; Breuer, Judith; Gershon, Anne A. et al

in BMC Medicine (2009), 7(26), 1-38

Varicella is a common viral disease affecting almost the entire birth cohort. Although usually self-limiting, some cases of varicella can be serious, with 2 to 6% of cases attending a general practice ... [more ▼]

Varicella is a common viral disease affecting almost the entire birth cohort. Although usually self-limiting, some cases of varicella can be serious, with 2 to 6% of cases attending a general practice resulting in complications. The hospitalisation rate for varicella in Europe ranges from 1.3 to 4.5 per 100,000 population/year and up to 10.1% of hospitalised patients report permanent or possible permanent sequelae (for example, scarring or ataxia). However, in many countries the epidemiology of varicella remains largely unknown or incomplete. In countries where routine childhood vaccination against varicella has been implemented, it has had a positive effect on disease prevention and control. Furthermore, mathematical models indicate that this intervention strategy may provide economic benefits for the individual and society. Despite this evidence and recommendations for varicella vaccination by official bodies such as the World Health Organization, and scientific experts in the field, the majority of European countries (with the exception of Germany and Greece) have delayed decisions on implementation of routine childhood varicella vaccination, choosing instead to vaccinate high-risk groups or not to vaccinate at all. In this paper, members of the Working Against Varicella in Europe group consider the practicalities of introducing routine childhood varicella vaccination in Europe, discussing the benefits and challenges of different vaccination options (vaccination vs. no vaccination, routine vaccination of infants vs. vaccination of susceptible adolescents or adults, two doses vs. one dose of varicella vaccine, monovalent varicella vaccines vs. tetravalent measles, mumps, rubella and varicella vaccines, as well as the optimal interval between two doses of measles, mumps, rubella and varicella vaccines). Assessment of the epidemiology of varicella in Europe and evidence for the effectiveness of varicella vaccination provides support for routine childhood programmes in Europe. Although European countries are faced with challenges or uncertainties that may have delayed implementation of a childhood vaccination programme, many of these concerns remain hypothetical and with new opportunities offered by combined measles, mumps, rubella and varicella vaccines, reassessment may be timely. In countries where routine childhood vaccination against varicella has been implemented, it has had a positive effect on disease prevention and control. Furthermore, mathematical models indicate that this intervention strategy may provide economic benefits for the individual and society. Despite this evidence and recommendations for varicella vaccination by official bodies such as the World Health Organization, and scientific experts in the field, the majority of European countries (with the exception of Germany and Greece) have delayed decisions on implementation of routine childhood varicella vaccination, choosing instead to vaccinate high-risk groups or not to vaccinate at all. In this paper, members of the Working Against Varicella in Europe group consider the practicalities of introducing routine childhood varicella vaccination in Europe, discussing the benefits and challenges of different vaccination options (vaccination vs. no vaccination, routine vaccination of infants vs. vaccination of susceptible adolescents or adults, two doses vs. one dose of varicella vaccine, monovalent varicella vaccines vs. tetravalent measles, mumps, rubella and varicella [MMRV] vaccines, as well as the optimal interval between two doses of MMRV vaccines). Assessment of the epidemiology of varicella in Europe and evidence for the effectiveness of varicella vaccination provides support for routine childhood programmes in Europe. Although European countries are faced with challenges or uncertainties that may have delayed implementation of a childhood vaccination programme, many of these concerns remain hypothetical and with new opportunities offered by combined MMRV vaccines, reassessment may be timely. [less ▲]

Detailed reference viewed: 213 (52 ULg)
Full Text
See detailDu numerus clausus en Médecine et en Sciences dentaires
Rentier, Bernard ULg

Speech/Talk (2008)

Detailed reference viewed: 31 (3 ULg)
Full Text
Peer Reviewed
See detailVaricella vaccination in Japan, South Korea, and Europe.
Sadzot-Delvaux, Catherine ULg; Rentier, Bernard ULg; Wutzler, Peter et al

in Journal of Infectious Diseases (2008), 197 Suppl 2

The most extensive use of varicella vaccine has been in the United States and Canada, where it is universally recommended. However, a number of other countries now have recommendations for use of the ... [more ▼]

The most extensive use of varicella vaccine has been in the United States and Canada, where it is universally recommended. However, a number of other countries now have recommendations for use of the vaccine, which has been expanding in Europe and Latin America. In this article, we review information concerning varicella vaccination in Japan, where the vaccine was first developed, and in South Korea and parts of Europe. Despite the worldwide availability of an efficient vaccine, varicella vaccination policy is highly variable from country to country. The recent development of a tetravalent vaccine against measles, mumps, rubella, and varicella could modify this variability in the future. It is evident that efforts to control varicella will spread gradually to all continents. [less ▲]

Detailed reference viewed: 51 (4 ULg)
Full Text
See detailDevenir mobile de corps et d’esprit
Rentier, Bernard ULg

Speech/Talk (2007)

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailIncreasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe : A role for the combined vaccine
Vesikari, Timo; Sadzot-Delvaux, Catherine ULg; Rentier, Bernard ULg et al

in Pediatric Infectious Disease Journal (2007), 26(7), 632-638

Universal mass vaccination according to a 2-dose measles-mumps-rubella (MMR) vaccine schedule is recommended by the World Health Organization and is fundamental to the control of these important diseases ... [more ▼]

Universal mass vaccination according to a 2-dose measles-mumps-rubella (MMR) vaccine schedule is recommended by the World Health Organization and is fundamental to the control of these important diseases. Very high coverage (first dose, >= 95%; second dose, >= 80%) is necessary to achieve and sustain high population immunity, and eventually interrupt indigenous transmission of these diseases. In 2006, the Advisory Committee on Immunization Practices issued a recommendation for 2 doses of varicella vaccine to be given universally to children. Coadministration of MMR and varicella vaccines, though efficacious and well tolerated, can be difficult because of the 2 separate injections and associated compliance issues. In addition to the general advantages of a combined vaccine, recently registered measles-mumps-rubella-varicella (MMRV) vaccines could facilitate introduction of varicella universal mass vaccination by simplifying administration and providing the potential to achieve high coverage rates for these 4 diseases. [less ▲]

Detailed reference viewed: 112 (27 ULg)
Full Text
See detailSe définir
Rentier, Bernard ULg

Speech/Talk (2006)

Detailed reference viewed: 12 (0 ULg)
Full Text
See detailOuvrir les yeux
Rentier, Bernard ULg

Speech/Talk (2005)

Detailed reference viewed: 15 (1 ULg)
Full Text
Peer Reviewed
See detailHCV genotypes 2 and 3: the predominant genotypes at the horizon 2020?
Delwaide, Jean ULg; Gerard, Christiane ULg; Vaira, Dolorès ULg et al

in Acta Gastro-Enterologica Belgica (2005, January), 68(1), 25

Detailed reference viewed: 60 (26 ULg)